cis-Bis(neodecanoato)(trans-(R,R)-1,2-diaminocyclohexane)platinum( II) [
L-NDDP] is a
liposome incorporated lipophilic
cisplatin analogue that has shown promising antitumor activity against
tumors resistant to
cisplatin and liver
metastases in mice.
L-NDDP is currently under clinical evaluation. However, NDDP is an isomeric mixture of different species having various isomeric neodecanoic moities as liganded leaving groups. A series of new highly
lipid-soluble cis-bis(neodecanoato)(trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) [Pt] complexes, using single isomers of
neodecanoic acid, were synthesized and characterized by analytical and spectroscopic techniques (infrared and 195Pt NMR). Multilamellar vesicles (MLVs) composed of
dimyristoylphosphatidylcholine (
DMPC) and
dimyristoylphosphatidylglycerol (
DMPG) at a molar ratio of 7:3 were used as carriers of the Pt complexes. The efficiency of incorporation of the liposomal-
platinum (L-Pt) preparations was greater than 95% and stability in
normal saline at 4 degrees C was greater than 95% at day 14 in each case. The iv LD50 values of all L-Pt preparations tested were in the range of 62.3 to 104 mg/kg. The % T/C obtained after a single ip injection of the optimal dose of L-Pt preparations against
L1210 leukemia was in the range of 150 to 253 (160 for
cisplatin). When a multiple ip injection schedule was used (on days 1, 5, and 9) the L-Pt preparations of R,R complexes (1, 7, and 9) were more active than
cisplatin at the optimal dose (% T/C = 257 for each vs 220 for
cisplatin). The L-Pt preparations of R,R complexes were also markedly active against
L1210 leukemia resistant to
cisplatin (% T/C 355, 231, and 185 respectively vs 112 for
cisplatin). These studies show that the single isomers of NDDP are comparable to the original isomeric mixture in terms of toxicity and
biological activity.